{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-23-000048","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.775514+00:00","generated_at":"2026-06-12T04:26:25.018070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros Q2 net loss $37.5M, cash $322M; plans KER-065 Phase 1 in DMD for Q1 2024","bullets":["Net loss of $37.5M in Q2 2023 vs $27.3M in Q2 2022, driven by increased R&D spend.","R&D expenses $32.5M (+$9.3M YoY) on pipeline advancement and manufacturing.","Cash and equivalents $322.0M as of June 30, 2023; expects runway into Q4 2025.","Phase 2 TROPOS trial of KER-012 in PAH cleared by FDA; webcast on trial design Aug 8.","KER-065 for Duchenne muscular dystrophy to start Phase 1 in healthy volunteers Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-23-000048","json":"https://secwatch.observer/filing/0001664710-23-000048.json","markdown":"https://secwatch.observer/filing/0001664710-23-000048.md","text":"https://secwatch.observer/filing/0001664710-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/0001664710-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/kros-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:26:25.018070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"042709487236bd5f26f778656a003c317a4c12f0","claim":"Keros Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income a net loss of $37.5 million.","evidence_excerpt":"Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/0001664710-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"a net loss of $37.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}